Since 1976, transgender women have been eligible to compete in the ladies' category at major tournaments such as Wimbledon, the United States Open, the Australian Open, and the French Open. Despite this, fifty years later, there has yet to be a transgender woman who has won a Grand Slam title.
In tennis, if a male athlete wishes to transition from the male to female category, the process typically requires the athlete to abstain from competition for several years.
The sport does not permit a male player to simply declare a gender change and immediately participate in female events at Wimbledon or other tournaments.
As both a researcher and a transgender athlete myself, I concur that no male athlete should be allowed to self-identify as female and compete in women’s categories without meeting established criteria.
For male athletes seeking to compete as females, the regulations specify strict hormonal requirements. They must undergo hormone therapy involving testosterone suppression and estrogen supplementation for a minimum of two years. During this period, they are required to maintain testosterone levels below 2.5 nmol/L and undergo additional physical assessments.
Such hormone treatment significantly impacts physical attributes related to athletic performance, including stamina, strength, recovery, and speed.
Research indicates that even in international sports such as cycling, transgender women lose their male advantage within one year of beginning hormone therapy. After three to four years of treatment, a male athlete would likely experience diminished physical capabilities, making it improbable to compete successfully or win at the Grand Slam level in women’s tennis.
https://t.co/EPBfBZDvRh